Disease Modification in Alzheimer's Disease: Current Thinking

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trials

Background:

• Alzheimer's disease (AD) presents a significant unmet medical need with no current cures or disease-slowing therapies.
• Altering the underlying disease progression through disease-modifying treatments is imperative for AD management.

Purpose of the Study:

• To review current regulatory guidance for demonstrating disease modification in Alzheimer's disease.
• To provide an overview of methodologies applicable to clinical trials for assessing disease modification.
• To aid in the design of future clinical trials targeting disease modification in AD.

Main Methods:

• Review of current regulatory documents and guidelines.
• Synthesis of existing methodologies for assessing disease modification in clinical trials.
• Analysis of applications of these methodologies in the context of neurodegenerative diseases.

Main Results:

• Identification of key regulatory requirements for demonstrating disease modification.
• Compilation of diverse methodologies for measuring treatment effects on AD pathology and progression.
• Discussion of the generalizability of these methods to other neurodegenerative conditions.

Conclusions:

• Clear demonstration of disease modification is essential for advancing AD therapeutics.
• Standardized methodologies and regulatory clarity will facilitate the development of effective AD treatments.
• The reviewed approaches offer a framework for evaluating disease-modifying therapies in AD and potentially other neurodegenerative disorders.